Javed Sarah, Hassan Jawad, Naz Maliha, Shan Saira, Abid Madiha, Shamsi Tahir Sultan
Department of Clinical and Molecular Cytogenetics, National Institute of Blood Disease and Bone Marrow Transplantation (NIBD), ST 2/A, Block 17, Gulshan-E-Iqbal, KDA Scheme 24, Karachi, 75300, Pakistan.
Research Department, NIBD, Karachi, Pakistan.
Mol Cytogenet. 2023 Feb 10;16(1):4. doi: 10.1186/s13039-022-00635-9.
To highlight the reasons of culture failure in bone marrow aspirate samples sent for Cytogenetic analysis and to identify the associated parameters causing this impact.
This is a retrospective cross-sectional study conducted in the Clinical and Molecular Cytogenetics Laboratory of NIBD Hospital, Karachi, Pakistan. The rates of culture failure are assessed from the year 2017-2020 along with their reasons. Bone Marrow aspirate samples of patients with hematological malignancies were cultured for chromosomal analysis, both at the time of diagnosis or relapse. Statistical analysis was performed using SPSS version 25.
A total of 1061 bone marrow aspirate samples were assessed for cytogenetic culture failures from the duration of 2017 to 2020. Ratio of males was predominantly higher i.e. 62.7% than female 37.3% with Mean ± SD age was 36.78 ± 18.94. Frequency of culture failure in the year 2020 was relatively high 20% as compared to the preceding years i.e. 8% in 2017, 6% in 2018, 7% in 2019. However, the patients were diagnosed with the following hematological malignancies; ALL 23%, CML 17.1%, AML 16.5% and AA 12.5%. Among the reasons of culture failure, cytogenetic analysis of patients with on-going chemo resulted in significant culture failures with p-value < 0.001 and the hematological malignancy, Acute Promyelocytic Leukemia, significantly impacted the growth of bone marrow aspirate cultures, with p-value < 0.001.
Significant findings were associated with causative factors of culture failure including on-going treatment and sample issues of clotted bone marrow as well as with the clinical diagnosis. These evaluations facilitated in overcoming the rise in culture failures. As per our knowledge, no such data, discussing the effects of various parameters such as sample quality, diagnosis, effects of treatment etc., has been documented previously.
强调送检进行细胞遗传学分析的骨髓穿刺样本培养失败的原因,并确定造成这种影响的相关参数。
这是一项在巴基斯坦卡拉奇NIBD医院临床和分子细胞遗传学实验室进行的回顾性横断面研究。评估了2017年至2020年期间的培养失败率及其原因。对血液系统恶性肿瘤患者的骨髓穿刺样本在诊断或复发时进行染色体分析培养。使用SPSS 25版进行统计分析。
在2017年至2020年期间,共评估了1061份骨髓穿刺样本的细胞遗传学培养失败情况。男性比例主要较高,即62.7%,女性为37.3%,平均年龄±标准差为36.78±18.94。2020年的培养失败频率相对较高,为20%,而前几年分别为:2017年8%,2018年6%,2019年7%。然而,患者被诊断患有以下血液系统恶性肿瘤:急性淋巴细胞白血病占23%,慢性粒细胞白血病占17.1%,急性髓细胞白血病占16.5%,再生障碍性贫血占12.5%。在培养失败的原因中,正在接受化疗的患者进行细胞遗传学分析导致显著的培养失败,p值<0.001,血液系统恶性肿瘤急性早幼粒细胞白血病对骨髓穿刺培养的生长有显著影响,p值<0.001。
重要发现与培养失败的致病因素有关,包括正在进行的治疗、骨髓凝血的样本问题以及临床诊断。这些评估有助于克服培养失败率的上升。据我们所知,以前没有记录过讨论样本质量、诊断、治疗效果等各种参数影响的数据。